Medical Marijuana

After the 2016 Presidential campaign dust has settled, Michigan NORML had a distrubing thought: with their states electoral votes as well as the White House going to Donald Trump and Governor Mike Pence, what will happen to the good people in Michigan who are being helped by the state’s medical marijuana program? Futhermore, how will cannabis policy change under the new administration at the federal level?
In that spirit, Michigan NORML crafted the letter below to send to Vice President-Elect Mike Pence in the hopes of gaining clarity and has recruited over 50 other NORML chapters from across the country to sign-on. 
Add your name to join NORML’s national network in keeping up the pressure to bring an end to the war on responsible marijuana users. 

Update: The Texas House of Representatives Calendar Committee refused to schedule a vote for HR 2107 and it will not recieve any futher consideration this session. Watch the video from the bills sponsors, State Representatives Eddie Lucio III and Jason Issac.

Update: The Texas House of Representatives Committee on Public Health approved HR 2107 on May 5 by a vote of 7-2. The bill will now be considered by the Calendars Committee to determine the date of the full House vote. 
Update: HB 2107 had a hearing on May 2 and after powerful targeted testimony, the number of cosponsors for the bill jumped from 5 to 75!
Update: A bipartisan House version of SB269 to legalize medical marijuana in the state of Texas has just been introduced by Representative Eddie Lucio III, D-Brownsville, titled HB 2107,
State Senator Jose Menendez has filed Senate Bill 269, currently making its way through committee, to protect qualified patients who consume cannabis and to provide for the state-licensed production and distribution of the plant.
SB 269 authorizes the possession, production, and distribution of medical marijuana and marijuana-infused products to qualified patients. Patients would receive cannabis through a network of private dispensaries and operators, similar to pharmacies, regulated under “strict guidelines” by the Texas Department of Public Safety. The state would use existing infrastructure and build upon the registry already established under the Compassionate Use Act, or SB 339, a 2015 bill Sen. Menendez co-authored and helped pass that lets patients with intractable epilepsy receive low-THC cannabis oil.
 
Thirty states and the District of Columbia have passed laws allowing patients access to cannabis therapy. Texas patients deserve these same protections.
 
Please enter your info below to contact your state elected officials and urge them to support this pending legislation. For more information please visit Texas NORML’s website or find your regional chapter here.

Senate lawmakers are only days away from taking a vote that may have a drastic impact on the future of marijuana policy.

Sessions recently was questioned by the Senate Judiciary Committee and during his confirmation hearing, he failed to give a straight answer with regard to how the Justice Department should respond to states that have legalized marijuana for medical or recreational use and left the door open for federal enforcement,

What is Senator Session’s record on marijuana policy? Think about this.

Senator Sessions has a long and consistent record of opposing any efforts to reform marijuana policy, and he once notoriously remarked that he thought the Ku Klux Klan “was okay until I found out they smoked pot.” He is a staunch proponent of the long-discredited ‘gateway theory,’ and has called on federal officials to return to the ‘Just Say No’ rhetoric of the 1980s. He was one of only 16 US Senators to receive a failing grade from NORML in our 2016 Congressional Report Card because of statements like these:

“We need grown-ups in charge in Washington to say marijuana is not the kind of thing that ought to be legalized, it ought not to be minimized, that it’s in fact a very real danger.”

“[Marijuana] cannot be played with, it is not funny, it’s not something to laugh about, and trying to send that message with clarity, that good people don’t smoke marijuana.”

During the 2015 confirmation hearings for outgoing US Attorney General Loretta Lynch, Sen. Sessions made clear that he opposed the Obama administration doctrine to allow states the flexibility to impose marijuana legalization absent federal interference, stating: “I hope that you will cease to be silent (on the issue of marijuana legalization), because if the law enforcement officers don’t do this, I don’t know who will. And in the past, attorneys general and other government officials have spoken out and I think kept bad decisions from being made.”

Fast-forward to today: Senator Sessions is on the cusp of becoming the top law enforcement officer in the United States. That is, unless your members of the US Senate hear a loud and clear message from you!

If confirmed by the US Senate to be US Attorney General, Sen. Sessions will possess the power to roll back decades of hard-fought gains. He will have the authority to challenge the medical marijuana programs that now operate in 29 states and the adult use legalization laws that have been approved in eight states. In short, the appointment of Sen. Sessions would be a step backwards at a time when the American public is demanding we push marijuana legalization forward. He is the wrong man for the job, and he represents a clear and present danger to the marijuana law reform movement. 

Please enter your information below to tell your Senates to ‘Just Say No’ to Sen. Sessions as Attorney General.

Update: The 2017 legislative session came to a close with lawmakers taking no further action on HB 110. However, legislators did approve a resolution establishing a task force to study marijuana legalization and make recommendations to the legislature by January 2018.
Please contact DE NORML to find out how you can help push reform in 2018. 
Update: Members of the House Revenue and Finance Committee voted 7 to 2 on May 10 to move HB 110 to the House floor. Because the measure seeks to amend criminal penalties, it requires a two-thirds majority from House members to move to the Senate for further consideration. The vote marks the first time that state lawmakers have ever approved legislation seeking to legalize and regulate the adult use marijuana market.
Update: Legislation, HB 110, the Delaware Marijuana Control Act, was introduced on March 30.
Senate Majority Whip Margaret Rose Henry has introduced HB 110 to legalize and regulate the adult use and retail sale of marijuana. The measure establishes a regulated commercial market for cannabis cultivation and retail sales, but does not permit unlicensed, home cultivation.

Senator Henry, the author of the state’s medical marijuana legislation said at a recent Medical Marijuana Act Oversight Committee meeting, “Education is suffering. Revenue from legalizing marijuana could help struggling schools and seniors, among other causes and close major budget deficits in Delaware.” 

According to recent polling data compiled by the University of Delaware, sixty-one percent of state voters favor legalizing marijuana.

Enter your information below to contact your lawmakers and urge them to side with the majority of Delaware voters.

Delaware is one of a growing number of states where lawmakers are considering regulating cannabis for adults. NORML will continue to update you in the coming weeks as this proposal is introduced and moves forward during legislative session. For more information on legislative efforts in Delaware, please contact Delaware NORML.

A bipartisan coalition of House and Senate lawmakers have proposed legislation, the Medical Marijuana Research Act of 2016, to expedite clinical investigations into the safety and efficacy of cannabis.

Passage of the measures — House Bill 5549 and Senate Bill 3077 — would expedite federal reviews of clinical protocols involving cannabis. It would also eliminate existing production limits for research grade cannabis and allow for investigators to access cannabis from sources other than NIDA’s University of Mississippi cultivation facility. It also mandates an FDA review of relevant cannabis studies to be performed within five years after the passage of the act.

Under present law, clinical investigations involving cannabis must meet approval from various federal agencies, including the DEA, the FDA, and the NIDA. Only cannabis provided by the NIDA may be used in clinical trials.

“Despite the fact that over 200 million Americans now have legal access to some form of medical marijuana, federal policy is blocking science. It’s outrageous,” said co-sponsor, Rep. Earl Blumenauer of Oregon in a prepared statement. “We owe it to patients and their families to allow for the research physicians need to understand marijuana’s benefits and risks and determine proper use and dosage. The federal government should get out of the way to allow for this long overdue research.”

Please contact your members of the US House and Senate and urge their support for these important measures.